Morgan Stanley Maintains Overweight on Edwards Lifesciences, Raises Price Target to $95
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Patrick Wood has maintained an Overweight rating on Edwards Lifesciences (NYSE:EW) and increased the price target from $80 to $95.
February 07, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has maintained an Overweight rating on Edwards Lifesciences and raised the price target from $80 to $95.
The increase in price target by a reputable analyst like Patrick Wood from Morgan Stanley is a strong positive signal for Edwards Lifesciences. It suggests confidence in the company's future performance and growth prospects, likely leading to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100